Artritis psoriásica

  1. Turrión Nieves, A.
  2. Martín Holguera, R.
  3. Movasat Hadjkan, A.
  4. Bohórquez Heras, C.
  5. Álvarez de Mon Soto, M.
Revue:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Année de publication: 2017

Titre de la publication: Enfermedades del sistema inmune y reumatológicas (III) Espondiloartritis. Manifestaciones cutáneas de las enfermedades reumatológicas

Serie: 12

Número: 26

Pages: 1508-1519

Type: Article

DOI: 10.1016/J.MED.2017.01.012 DIALNET GOOGLE SCHOLAR

D'autres publications dans: Medicine: Programa de Formación Médica Continuada Acreditado

Résumé

Introduction Psoriasic arthritis (PsA) is an inflammatory musculoskeletal disease that displays at least three of the following symptoms: psoriasis, nail dystrophy, dactylitis, negative rheumatoid factor or juxta-articular new bone formation. Epidemiology Prevalence is estimated in 0.5% of the population, with an annual incidence of 4-8 cases per 100,000 inhabitants per year. It can develop at any age. It is a very heterogeneous disease regarding to the different forms of joint involvement. Etiopathogenesis Multiple theories have been established when it comes to its etiopathogenesis, so in a genetically predisposed individual the action of a harmful agent triggers a self-perpetuating inflammatory process over time, thus causing a structural lesion due to either the inflammation itself or to the associated repair processes. Clinical manifestations Patients present joint swelling, enthesitis, dactylitis, nail/skin involvement. Aside from enthesopathies or spondylitis, other polyarticular clinical forms can appear which are similar to rheumatoid arthritis, also distal interphalangeal involvement and, more rarely, mutilans form. Diagnosis Diagnosis is mostly clinical since there are no pathognomonic analytical features. Prognosis and treatment Prognosis is poor is left to its natural progress, though there are cases that remit spontaneously, it is common they require a tratment that avoids structural progress. Some clinical forms do not respond to traditional treatments with DMARDs and/or NSAIDs, thus requiring biological drugs.

Références bibliographiques

  • Cantini F, Niccoli L, Nannini C, Kaloudi O, Bertoni M, Cassara E. Psoriatic arthritis: a systematic review. Int J Rheum Dis. 2010;13(4):300-17.
  • Wright V, Moll JM. Psoriatic arthritis. Bull Rheum Dis. 1971;21(5):627-32.
  • Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: deve-lopment of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665-73.
  • Fernández Sueiro JL, Pertegaz Diaz S. Nuevos criterios de Clasi-ficación en la artritis psoriasica. Reumatol Clin. 2007;3Supl2:10-4.
  • Torre Alonso JC. Use and application in clinical practice of the CASPAR criteria. Reumatol Clin. 2010;6S1:18-21.
  • Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5): 496-509.
  • Alwan W, Nestle FO. Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine. Clin Exp Rheuma-tol. 2015;33(5)Suppl93:S2-6.
  • Naik S, Bouladoux N, Wilhelm C, Molloy MJ, Salcedo R, Kastenmuller W. Compartmentalized control of skin immunity by resident com-mensals. Science. 2012;337(6098):1115-9.
  • Van Baarsen LG, Lebre MC, van der Coelen D, Aarrass S, Tang MW, Ramwadhdoebe TH. Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy? Arthritis Res Ther. 2014;16(4):426-014-0426-z.
  • McGonagle D, Benjamin M, Tan AL. The pathogenesis of psoriatic arthritis and associated nail disease: not autoimmune after all? Curr Opin Rheumatol. 2009;21(4):340-7
  • Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J. IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012;18(7):1069-76
  • Benham H, Norris P, Goodall J, Wechalekar MD, FitzGerald O, Szent-petery A. Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Res Ther. 2013;15(5):R136.
  • Raychaudhuri SK, Saxena A, Raychaudhuri SP. Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis. Clin Rheu-matol. 2015;34(6):1019-23.
  • Dauden E, Castaneda S, Suarez C, García-Campayo J, Blasco AJ, Aguilar MD. Integrated approach to comorbidity in patients with psoriasis.Working Group on Psoriasis associated Comorbidities. Actas Dermosifiliogr. 2012;103Suppl1:1-64.
  • Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Der-matol. 1999;135(12):1490-3.
  • Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasis. J Invest Dermatol. 2006;126(10):2194-201.
  • Pouplard C, Brenaut E, Horreau C, Barnetche T, Misery L, Richard MA. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol. 2013;27Suppl3: 36-46.
  • Langevitz P, Buskila D, Gladman DD. Psoriatic arthritis precipitated by physical trauma. J Rheumatol. 1990;17(5):695-7.
  • Gladman DD, Farewell VT, Nadeau C. Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol. 1995;22(4):675-9.
  • Coates LC, Helliwell PS. Disease measurement--enthesitis, skin, nails, spine and dactylitis. Best Pract Res Clin Rheumatol. 2010;24(5):659-70.
  • Anandarajah AP, Ritchlin CT. The diagnosis and treatment of early psoriatic arthritis. Nat Rev Rheumatol. 2009;5(11):634-41.
  • Jones G, Crotty M, Brooks P. Interventions for psoriatic arthritis. Cochrane Database Syst Rev. 2000;(3)(3):CD000212.
  • Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis. 2005;64Suppl2:ii74-7.
  • Pchelintseva AO, Korotaeva TV, Godzenko AA, Korsakova I, Stanislav ML, Denisov LN. Results of leflunomide treatment of psoriatic arthritis. Ter Arkh. 2007;79(8):22-8.
  • Deeks ED. Apremilast: A review in psoriasis and psoriatic arthritis. Drugs. 2015;75(12):1393-403.
  • Mease PJ. Psoriatic arthritis treatment update. Bull NYU Hosp Jt Dis. 2011;69(3):243-9.
  • Partsch G, Steiner G, Leeb BF, Dunky A, Broll H, Smolen JS. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol. 1997;24(3):518-23.
  • Benjamin M, McGonagle D. Basic concepts of enthesis biology and immunology. J Rheumatol Suppl. 2009;83:12-3.
  • McGonagle D, Gibbon W, O’Connor P, Green M, Pease C, Emery P. Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum. 1998;41(4):694-700.
  • Mumtaz A, Gallagher P, Kirby B, Waxman R, Coates LC, Veale JD. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis. 2011;70(2):272-7.
  • Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol. 2008;35(5):883-90.
  • Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis: a literature review from a global health systems perspective. P T. 2010;35(12): 680-9.
  • Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK. Adverse effects of biologics: a network meta-analy- sis and Cochrane overview. Cochrane Database Syst Rev. 2011;(2)(2): CD008794.
  • Ibáñez Bosch R. Management of difficult clinical situations in rheumatoid arthritis: hepatitis. Reumatol Clin. 2009;5S1:53-60.
  • Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373(9664):633-40.
  • Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis. 2014;73(1):95-100.
  • Ogata A, Umegaki N, Katayama I, Kumanogoh A, Tanaka T. Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. Joint Bone Spine. 2012;79(1):85-7.
  • Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499-510.
  • Ash Z, Gaujoux-Viala C, Gossec L, Hensor EM, FitzGerald O, Winthrop K. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2012;71(3):319-26.
  • Elyoussfi S, Thomas BJ, Ciurtin C. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies. Rheumatol Int. 2016;36(5):603-12.
La source de données: Dialnet